



This PDF file is an excerpt from the EPA guidance document entitled *Permit Guidance Document: Pharmaceutical Manufacturing Point Source Category* (40 CFR Part 439). You can download the complete document from <http://www.epa.gov/waterscience/guide/pharm/guidance/>

## **Title Pages, Disclaimer & Executive Summary**



# **Permit Guidance Document: Pharmaceutical Manufacturing Point Source Category (40 CFR Part 439)**

January 2006

Permit Guidance Document: Pharmaceutical Manufacturing Point  
Source Category (40 CFR Part 439)

U.S. Environmental Protection Agency  
Office of Water  
Engineering and Analysis Division  
1200 Pennsylvania Avenue, NW (4303T)  
Washington, DC 20460

EPA 821-F-05-006

January 2006

# Disclaimer

The discussion in this document is intended solely as guidance. The statutory provisions and regulations of the U.S. Environmental Protection Agency (EPA) described in this document contain legally binding requirements. This document is not a regulation itself, nor does it change or substitute for those provisions and regulations. Thus, it does not impose legally binding requirements on EPA, States or the regulated community. This guidance does not confer legal rights or impose legal obligations upon any member of the public.

While EPA has made every effort to ensure the accuracy of the discussion in this guidance, the obligations of the regulated community are determined by statutes, regulations or other legally binding requirements. In the event of a conflict between the discussion in this document and any statute or regulation, this document would not be controlling.

The general descriptions provided here may not apply to particular situations based upon the circumstances. Interested parties are free to raise questions and objections about the substance of this guidance and the appropriateness of the application of this guidance to a particular situation. EPA and other decision makers retain the discretion to adopt approaches on a case-by-case basis that differ from those described in this guidance where appropriate.

Mention of trade names or commercial products does not constitute an endorsement or recommendation for their use.

This document may be revised periodically without public notice. EPA welcomes public input on this document at any time.

# Executive Summary

On September 21, 1998, the U.S. Environmental Protection Agency (EPA) promulgated revised regulations for the pharmaceutical industry to control both effluent discharges and air emissions. The purpose of this guidance document is to help permit writers and pretreatment coordinators develop appropriate National Pollutant Discharge Elimination System (NPDES) permits and pretreatment requirements for pharmaceutical facilities with the following types of operations: fermentation, extraction, chemical synthesis, mixing, compounding and formulating and research. For an overview of the NPDES and National Pretreatment Programs, refer to the *U.S. EPA NPDES Permit Writer's Manual* (EPA-833-B-96-003) as well as the *Industrial User Permitting Guidance Manual* (EPA-833/R-89-001).